1	A novel framework for assessing causal effect of
2	microbiome on health: long-term antibiotic usage
3	as an instrument
4 5	Nele Taba ¹ , Krista Fischer ^{1,2} , Estonian Biobank research team ¹ , Elin Org ^{1*#} & Oliver Aasmets ^{1*#}
6	
7	Affiliations
8	¹ Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia
9 10 11	² Institute of Mathematics and Statistics, Faculty of Science and Technology, University of Tartu, Tartu, Estonia
12	Collaborators
13 14	Estonian Biobank research team: Mait Metspalu, Andres Metspalu, Lili Milani, Tõnu Esko
15	
16	
17	
18	*These authors contributed equally: Elin Org & Oliver Aasmets
19	[#] Corresponding authors: Elin Org & Oliver Aasmets
20	Institute of Genomics, Estonian Genome Centre
21	University of Tartu
22	Tartu 51010, Estonia
23	phone: (372) 737 4034; fax: (372) 737 4060
24	Email: <u>elin.org@ut.ee</u> , <u>oliver.aasmets@ut.ee</u>
25	
26	
27	Keywords: gut microbiome, electronic health registries, antibiotics, causal inference
28	Word count: 4731
29	Number of Figures: 3

30 Abstract

31 Assessing causality is undoubtedly one of the key questions in microbiome studies for the 32 upcoming years. Since randomised trials in human subjects are often unethical or difficult to 33 pursue, analytical methods to derive causal effects from observational data deserve attention. 34 As simple covariate adjustment is not likely to account for all potential confounders, the idea 35 of instrumental variable (IV) analysis is worth exploiting. Here we propose a novel framework 36 of antibiotic instrumental variable regression (AB-IVR) for estimating the causal relationships 37 between microbiome and various diseases. We rely on the recent studies showing that 38 antibiotic treatment has a cumulative long-term effect on the microbiome, resulting in 39 individuals with higher antibiotic usage to have a more perturbed microbiome. We apply the 40 AB-IVR method on the Estonian Biobank data and show that the microbiome has a causal 41 role in numerous diseases including migraine, depression and irritable bowel syndrome. We show with a plethora of sensitivity analyses that the identified causal effects are robust, and 42 43 propose ways for further methodological developments.

44 Introduction

45 Human microbiome studies have demonstrated that the gut microbiome can be affected by various exposures such as diet and medications^{1,2} and changes in the gut microbiome 46 47 composition have been associated with the prevalence or susceptibility to complex diseases such as type 2 diabetes^{3–5}, Crohn's disease⁶ and different cancers^{7,8}. However, with the 48 primary interest in disease associations, determining the causal effects has remained 49 50 challenging, as there are several potential confounders (dietary choices, other behavioural 51 and environmental exposures) that may affect microbiome and their disease outcomes via 52 different pathways. Experimental studies, such as utilising faecal microbiota transplantation, 53 have proven a causal mechanistic link between treatment, microbiome and health⁹, but to date 54 the methods for determining such causal associations noninvasively are limited¹⁰. An 55 alternative would be to attempt causal effect estimation based on observational cohort data -56 using Instrumental Variable (IV) method to avoid biases due to unobserved confounding. One 57 example of such an approach is Mendelian Randomization (MR), where a genetic variable 58 acts as an instrument (affecting only the exposure variables, thus microbiota, but not directly the outcome or the confounders). Successful examples include studies that have shown the 59 causal role of several taxa on cancers¹¹, inflammatory bowel diseases¹² and depression¹³. 60 However, MR is limited by the lack of valid genetic instruments - this might remain an issue 61 62 even with larger sample sizes, since microbiome is shown to be with low heritability^{14,15}. To fill 63 this void, we propose a new analytical approach to assess the causal role of microbiome on

64 health: antibiotic instrumental variable regression (AB-IVR), using the long-term history of 65 antibiotic usage (hAB) as an instrument.

66 Antibiotic (AB) usage is shown to affect microbiome in the long term in a cumulative manner, 67 whereby larger number of antibiotics prescribed in the past results in a more perturbed microbiome composition^{2,16}. This means that there are on average consistent differences in 68 microbiome between the individuals with higher and lower long-term antibiotics usage. 69 70 Importantly, this long-term usage effect is already evident in subjects who have taken only 3-71 5 courses of AB in the last 10 years before the sample collection. Such antibiotic consumption 72 is highly common in the general population. This, and the fact that antibiotics are expected to 73 affect health primarily via microbiome (directly eliminating the disease-causing bacteria, but 74 also resulting in a general dysbiosis as a "collateral damage") and not via any other pathways, 75 made us ponder whether hAB - measured as number or antibiotics prescribed during 10 years 76 prior to microbiome sampling - can serve as a natural experiment randomising individuals to 77 have more or less perturbed microbiome. Thus, we propose that by using hAB as an 78 instrument, we can compare the disease incidence between groups that have consistent long-79 term differences in microbiome, and by this assess the causal role of microbiome in disease. 80 Of note, the primary focus of the AB-IVR method is on diseases, which itself are not treated 81 with antibiotics. We consider the AB-IVR method as an intermediate option between the 82 observational studies and randomised trials: we aim to gather more information compared to 83 observational studies, but still do not see it as an equivalent alternative to the randomised 84 trials.


85 Next sections introduce the AB-IVR methodology and its usage on the Estonian Biobank 86 samples. Firstly, we introduce the method as a Two-Sample Two-Stage Least Squares 87 (TSTSLS) procedure and the corresponding sample sets that we utilise for estimating the causal effects. Next, we introduce the concept of long-term antibiotics usage as an instrument. 88 89 We discuss model assumptions and limitations that can bias the results such as the scope of 90 the estimable effects, feedback loops arising from the bidirectional microbiome-disease 91 crosstalk and effects of general health behaviour. Lastly, we assess the causal role of 92 microbiome in several common diseases, test the validity of the findings through a series of 93 sensitivity analyses and give insights for future developments. The AB-IVR method showed 94 that microbiome has a causal effect for several common diseases such as irritable bowel 95 syndrome, migraine and depression, and we believe that it opens up new possibilities for 96 causal discovery in the human microbiome field.

97 Results

98 Study overview and data selection

99 For inferring the causal effect of microbiome on disease we utilised the method of Two-Sample Two-Stage Least Squares (TSTSLS), which is a special case of instrumental variable 100 regression. In our case, the history of antibiotics usage (hAB) serves as the instrumental 101 102 variable, hence the term antibiotic instrumental variable regression, AB-IVR (Fig. 1A). The 103 general idea of the method is that when AB usage cannot realistically have any direct effect on the disease of interest, the correlation of AB usage with the disease incidence can only 104 105 arise via mediation by microbiome. Thus the total effect of hAB on the disease outcome can 106 be decomposed into the effect of hAB on the microbiome and the causal effect of the 107 microbiome on the outcome. As the total effect and the effect of hAB on the microbiome are 108 estimable, also the causal effect of the microbiome becomes identifiable.

109 In our study, the TSTSLS methodology relies on two independent datasets which are used for 110 1) estimating the effect of hAB on disease ($\beta_{\text{D,hAB}}$) and 2) estimating the effect of hAB on the 111 microbiome ($\beta_{MB,hAB}$). The two effects are combined to evaluate the causal effect of 112 microbiome on disease ($\beta_{D,MB}$)(Fig. 1A). For estimating the effect of hAB on disease, we 113 leveraged the electronic health records data available for the Estonian Biobank (EstBB) participants (N > 210 000)¹⁷. As prevalent diseases can have an effect on the microbiome and 114 potentially create a feedback loop, which biases the results, we analysed the effect of previous 115 116 antibiotics usage on the incident diseases instead (See Methods). To estimate the effect of hAB on the microbiome, we used Estonian Microbiome (EstMB, a subcohort of EstBB) cohort 117 118 (N > 2500) samples with shotgun metagenomics data available².



119


120 Figure 1. Graphical description of the study design. Upper panel (A) illustrates the instrumental 121 variable regression and corresponding assumptions schematically in the context of our study. hAB -122 history of antibiotic usage; MB - microbiome; D - disease; C - confounder. Lower panel (B) illustrates 123 the samples and data used. Sample 1 refers to the sample where disease follow-up data is recorded, 124 EstBB in our case. Sample 2 refers to the sample where the microbiome is assessed, EstMB in our 125 case. We recorded the AB usage as the number of AB prescribed (total and AB subgroups) during the 126 10-year period preceding the start of follow up in Sample 1 and microbiome sampling in Sample 2, 127 whereas in both samples the individuals receiving AB during the last 6 months of the aforementioned 128 period are excluded. Sample 1 was followed up for incident outcomes of 56 common diseases from 129 01.01.2015 until 31.12.2022, whereafter observations are right censored irrespective of the future 130 outcomes. In Sample 2 the microbiome was assessed on an arbitrary moment between November 2017 131 to July 2020. The causal effect of MB on disease ($\beta_{D,MB}$) in the two-sample setting is estimated as the 132 ratio of the effect of AB-usage on disease ($\beta_{D,hAB}$) in Sample1 (EstBB) and the effect of AB-usage on 133 MB ($\beta_{MB,hAB}$) in Sample2 (EstMB).

History of antibiotics usage as a valid instrument 134

135 Estimating the causal effects by instrumental variable regression analysis relies on several 136 assumptions. Firstly, the hAB must be associated with the gut microbiome (Fig. 1A). We and

137 others have previously shown that hAB is associated with the microbiome composition

138 additively, meaning that higher hAB is associated with larger changes in the microbiome composition^{2,16}. Here, we focused our analysis on the *Prevotella/Bacteroides* ratio (P/B ratio) 139 140 that represents a summarised state of microbiome by reflecting the enterotype composition¹⁸. 141 We confirm the additive effect of total hAB on P/B ratio and show that it also holds for different 142 classes of antibiotics, namely macrolides (ATC code J01FA), penicillins (J01CR) and 143 fluoroquinolones (J01MA), which we will use for the sensitivity analysis (Fig. 2A). It must be 144 highlighted that the different antibiotics classes are largely uncorrelated in their usage and 145 their long-term effects on the microbiome composition differ (Fig. 2B, Fig. 2C).



146

147 Figure 2. Antibiotic usage in the EstMB cohort. Panel A shows the association between the number 148 of different antibiotics used during the last 10 years before the sample collection and Prevotella-149 Bacteroides ratio. The total AB usage and usage of all AB subclasses was strongly associated with 150 Prevotella/Bacteroides ratio (combined AB usage p=2.04e-8, macrolides p=0.0192, fluoroquinolones 151 p=3.03e-5, and penicillins p=0.0026). Panel **B** shows the Spearman correlation between the number of different antibiotics classes used during the last 10 years before the sample collection. Panel C shows 152 153 the unique and shared hits of the univariate analyses associating the antibiotics usage history with the 154 abundance of microbial species. Panel D shows the proportion of cohort participants by the number of 155 antibiotics used during the past 10 years.

Fluoroquinolones (J01MA)

Number of antibiotic courses in 10 years

(J01CR)

156


157 Secondly, the usage of antibiotics and the disease cannot have any common cause. This 158 assumption can be easily violated when prevalent disease cases are analysed. Namely, the 159 disease could for example weaken the immune system, which would in turn result in higher 160 antibiotics consumption, often referred to as a "feedback loop". We address this issue by 161 analysing only incident disease cases that are observed during the follow-up period (thus after 162 the period where AB usage was recorded). As a sensitivity analysis we additionally analyse

163 disease cases that have been diagnosed more than 5 years after the sample collection, to 164 eliminate the possibility of prevalent diseases that have not yet been diagnosed, but are 165 already present and affecting the microbiome composition. Violation of the second assumption 166 can also occur when subjects of poorer health are studied, since these individuals are more 167 likely to take a larger number of antibiotics and develop further comorbidities. For example, 168 elderly individuals are likely to have weaker immunity and therefore take a larger number of 169 antibiotics, but at the same time they are at higher risk of various comorbidities. Thus an overall 170 frailty level could act as a confounder. To address this concern, we focus our analysis only on 171 younger people (ages 23-50), who have taken up to 5 courses of antibiotics during 10 years 172 prior to microbiome sampling or start of follow-up (See Methods, **Fig. 1**). The lower limit for 173 age refers to the minimum age in the EstMB cohort. The chosen threshold for the number of 174 antibiotics courses is highly common in the population, thus it is meant to represent the 175 healthier part of the population (Fig. 2D), allowing us to exclude individuals with chronic and 176 extreme AB usage. As sensitivity analyses, we study older people, extending the age range 177 to 89 (refers to the maximum age in EstMB cohort), and usage of antibiotics up to 10 courses. 178 Thirdly, antibiotics cannot have a direct effect on the disease that is not mediated by the 179 microbiome composition. Although some authors have indicated that antibiotics can have such 180 microbiome-independent effects, the evidence is currently weak and we consider that most of 181 the effect is based on altering the microbiome composition¹⁹.

182 Causal role of the microbiome on diverse disease groups confirmed with the novel AB-183 IVR framework

184 We applied the AB-IVR methodology to assess whether the microbiome has a causal role for 185 the development of 56 conditions across diverse disease groups. We focused primarily on 186 common chronic diseases and cancers where antibiotics are not used as a treatment and 187 which had at least 50 incident cases. Due to the broad selection of diseases, we did not apply 188 any disease specific inclusion and exclusion criteria, but future studies should take the disease 189 specificity into account. Antibiotics have a complex effect on MB via altering the abundances 190 of several members of the composition simultaneously. Therefore, when the analysis is based 191 on general hAB, various taxa are altered simultaneously and thus it is not possible to imply 192 which specific species or genera are the culprit in disease formation. This is a limitation of our 193 methodology and remains a challenge to be solved by future improvements. Therefore, 194 instead of using the data of specific species or genera to characterise the changes in the 195 microbiome, we analysed the effect of Prevotella-Bacteroides (P/B) ratio, which reflects the 196 general state of the microbiome.

197 In total, the microbiome was identified to have a causal effect on 23 diseases (FDR ≤ 0.05) 198 (Fig. 3A, Supplementary Fig. 1, Supplementary Table 1). These diseases include 199 cardiometabolic diseases like cardiac arrhythmias, intestinal diseases like irritable bowel 200 syndrome and gastro-esophageal reflux disease, skin diseases like atopic dermatitis and 201 acne, and several mental disorders like anxiety disorders and depression. The causal 202 estimates are largest for lactose intolerance, migraine and irritable bowel syndrome with the 203 dominance of *Prevotella* defending against the disease progression. Notably, we did not 204 identify the causal effect of the microbiome on any of the cancers studied, which is likely due 205 to excluding older individuals from the analysis.



206

207 Figure 3. Results of the main AB-IVR analysis (A) and sensitivity analyses (B,C). On panels A,B, 208 and C the causal effect estimate of Prevotella/Bacteroides ratio on a selection of diseases is presented 209 (full results comprising all diseases analysed can be viewed in Supplementary Tables 1, 3-5, and 6-210 8). In panel A the age is filtered as 23-50, maximum number of AB prescribed is five, and minimum 211 number of cases per disease is 50. Panel B represents the sensitivity analyses where sample formation 212 varies, whereas the main analysis is depicted for comparison in red. Green shows the effect estimates, 213 when age is filtered as 23-89; light-purple shows the effect estimates, when the maximum number of 214 AB prescribed is 10; dark-purple describes the scenario where the first five years of incidence after the 215 start of follow-up is considered as prevalent disease. Panel C represents the sensitivity analyses where 216 information regarding subclasses of AB were used instead of the total amount of AB prescribed, 217 whereas other settings were identical to the main analysis. Red corresponds to the main analysis (same 218 as A), dark blue corresponds to the class of penicillins (J01CR), light-blue corresponds to the class of 219 macrolides (J01FA) and light-green corresponds to the class of fluoroquinolones (J01MA).

Sensitivity analysis and assessment of different antibiotics as instruments 220

221 We carried out several sensitivity analyses to assess the validity of the model estimates.

222 Firstly, we simulated random binary variables with different event probabilities to see how our

223 approach behaves in a scenario where no effect is expected. Indeed, the method did not

224 identify any effects and manages to control the false discovery rate perfectly (Supplementary 225 Table 2). Next, we focused on different scenarios which would test the model behaviour when 226 the study population includes subjects who are more likely to have health complications, thus 227 testing the second model assumption. For that we considered subjects up to 89 years old 228 (refers to the maximum age in EstMB cohort), subjects that had been prescribed antibiotics 229 up to 10 times during 10 years prior to microbiome sample collection or start of follow-up, and 230 considering a 5 year "gap" in defining the incident cases after the start of follow-up (Fig. 3B. 231 Supplementary Fig. 2, Supplementary Tables 3, 4, 5). The reasoning behind the chosen 232 sensitivity analyses is discussed in detail in the Methods. We observed no major differences 233 in the estimated causal effects for any of the tested scenarios. Most notably, the causal 234 estimates for diseases that showed strongest effects in the primary analysis remained largely 235 untouched by the scenarios tested. This includes diseases like migraine, irritable bowel 236 syndrome, chronic rhinitis and depression. Lastly, we carried out sensitivity analysis to test 237 the performance of different antibiotics subclasses as instruments (Fig. 3C, Supplementary 238 Tables 6, 7, 8). Again, the results remained similar and the previously highlighted causal 239 estimates remained largely unchanged and independent of the chosen instrument. Since 240 different antibiotics classes are largely uncorrelated in their usage and their long-term effects 241 on the microbiome composition differs (Fig. 2B, Fig. 2C), the differences between the effect 242 estimates can originate from the varying targets of antibiotic subclasses and can refer to 243 divergent patterns in influenced subcommunities. This might be the case for gout where using 244 macrolides and fluoroquinolones as instruments results in causal effect estimates with 245 opposite directions, but with the total antibiotics usage as an instrument, no causal effect is 246 identified (Supplementary Fig. 3). However, the overall similarity of the estimates for most of 247 the diseases confirms the underlying causal effect of the microbiome as a whole. Lastly, since 248 the logarithm of the P/B ratio is with a bimodal distribution, we additionally performed an 249 analysis where the P/B ratio was inverse normal transformed. However, we did not observe 250 any notable discrepancies compared to the main analysis (Supplementary Fig. 1, 251 Supplementary Table 9).

Discussion 252

253 We introduce and demonstrate an analytical approach that expands the causal inference 254 toolbox for microbiome studies by using long-term antibiotics usage as an instrument in an 255 instrumental variable regression setting. We show that the history of antibiotics usage can be 256 a valid instrument and that the microbiome has a causal role for several diseases, such as 257 migraine, irritable bowel syndrome, depression and many others.

258 Establishing the causal role of microbiome in complex diseases can involve different levels of 259 evidence from the identification of disease associations and faecal microbiota transplantations (FMT) to understanding the molecular mechanisms that produce the phenotype²⁰. While the 260 261 established knowledge about the mechanisms of microbial strains or microbial metabolites 262 remains scarce, computational approaches and FMT studies have been used to show the 263 causal role of microbiome in several conditions²⁰. In line with our findings, Mendelian 264 randomization studies have identified the causal role of microbial taxa for migraine²¹, irritable 265 bowel syndrome²² and depression^{13,23}. Nevertheless, MR studies have indicated the causal role of microbiome in type 2 diabetes²³, psoriasis²⁴, inflammatory bowel diseases¹² and heart 266 267 failure²⁵, which was inconsistent with our findings. However, these inconsistencies can be 268 expected as our approach focuses on the general effects of the microbiome composition, 269 which is more in line with how the FMT studies can inform causality. Then again, FMT studies 270 are coupled with challenges such as screening and processing the FMT material and selection 271 of the donor and the mode of delivery²⁶. Additionally, the gut microbiome and lifestyle of the 272 recipient can significantly alter the success of the FMT²⁶. Therefore, although FMT has been shown to transmit or alleviate hypertension²⁷, IBD²⁸ and insulin sensitivity^{29,30}, the results can 273 be conflicting^{28,31}. Thus, we believe that in the quest for establishing the causal effects, our 274 275 approach can provide an additional layer of evidence that combines features from the MR and 276 FMT approaches.

277 Antibiotics are meant to kill or inhibit the growth of bacteria and are commonly directly or 278 indirectly effective against several members of the microbial community³². Therefore, using 279 long term usage of antibiotics as an instrument allows us to estimate the causal effect of the 280 disturbed part of the community. This brings along two limitations for the proposed 281 methodology: we cannot identify the effects of single members of the community; and we 282 cannot rule out the potential causal effects of the members that are unaffected by the 283 antibiotics used. Thus, the microbiome can still be causal for the development of diseases for 284 which our proposed methodology did not show a causal effect. Tackling these limitations 285 opens up several directions for future development. Since different antibiotic subgroups are 286 intended to have an effect on different bacteria, one can use or design instruments that are 287 specific to certain subcommunities or taxa to estimate the causal effects of interest. Also, 288 several instruments such as long-term usage of different antibiotic subclasses and other drugs 289 with persistent effects on microbiome can be combined and used simultaneously, which in turn opens the opportunity to utilise various sensitivity analyses that are developed for 2-290 291 sample Mendelian Randomization framework. For example, consumption of numerous host-292 targeted drugs are known to affect the microbiome^{16,33} and antidepressants have also been 293 shown to have long term effects³⁴, but as microbiome-related research is currently rapidly

evolving, many more suitable instruments, not limited to medications, are likely emerging in the near future.

296 Here, we showed in principle how long-term effects of antibiotics can be used to identify the 297 causal role of the microbiome in a large set of common diseases. However, certain limitations 298 must be kept in mind while interpreting the results for a specific outcome. We did not focus 299 separately on any single disease, thus future studies should consider disease-specific 300 inclusion-exclusion criteria when designing the study. An important consideration concerns 301 the role of general health behaviour. It is possible that the overall awareness and interest in 302 one's health promotes the usage of antibiotics, which also indirectly changes the disease risks. 303 Variables such as gender and education might entail general health behaviour and 304 consequently simultaneously affect AB-usage and health-outcomes (eg. individuals with 305 higher education might seek more help from health-care professionals (thus have different 306 AB-consumption habits), have better eating habits, smoke less, be more physically active etc). 307 Therefore we advise any future studies using AB-IVR framework to account for such possible 308 confounders. Lastly, the amount of antibiotic consumption is highly variable in different populations and antibiotic consumption in Estonia is among the lowest in Europe³⁵. Thus, the 309 310 results need to be validated in different populations to account for the differences in overall 311 burden of antibiotics usage.

We demonstrated a novel AB-IVR approach by assessing the effect of *Prevotella/Bacteroides* ratio on a large set of diseases. The results confirmed the utility of the introduced method and we believe it has large potential to become a new widely used framework that allows to assess analytically the causal effect of microbiome on health. Further research with disease-specific inclusion-exclusion criteria is warranted for drawing conclusions about specific health-effects and several exciting future development options arised.

318

319 Methods

320 Sample description

The proposed method combines the information from two different samples, whereas the association between the instrument and the exposure is analysed in one sample and the association between the instrument and the outcome in another sample (**Fig. 1**). In our case the association between antibiotics usage and microbiome is assessed in the Estonian Microbiome Cohort² and association between antibiotics usage and diseases in the Estonian Biobank data¹⁷.

327 The Estonian Biobank (EstBB) is a volunteer-based population cohort initiated in 1999 that 328 currently includes over 210,000 genotyped adults (≥ 18 years old) across Estonia. Estonian 329 Microbiome Cohort (EstMB) was initiated in 2017 when more than 2500 EstBB participants, who 330 joined the EstBB at least 10 years before, provided stool, oral, and blood samples. The EstMB cohort, 331 microbiome sample collection, stool bacterial DNA extraction and shotgun metagenomic sequencing are described in detail in Aasmets & Krigul et al.². For the current project, taxonomic profiling of 332 the gut microbiome was carried out using *MetaPhIAn3 too*^{β 6}. The *Prevotella-Bacteroides* ratio, 333 334 which we considered as the primary indicator of the microbiome inter-individual variability in 335 our analysis, was calculated on the genus level after imputing zeros with a pseudocount equal 336 to half of the minimal non-zero relative abundance observed in the data. For both, EstMB and EstBB one of the major advantages is the possibility to use electronic health records (EHR) 337 338 data and follow the participants' health both retrospectively and prospectively. Using EHR, we 339 obtained the data for the history of antibiotics usage and the disease incidence. The EstMB 340 participants were removed from the EstBB sample to ensure that the two samples are 341 independent.

342 Start of follow-up

343 An important aspect in the following data-processing is the moment when MB is collected in 344 Sample 2 (EstMB) and the follow-up starts in Sample 1 (EstBB) (Fig. 1). Of note, since the 345 proposed methodology uses two independent samples, the MB collection and start of follow-346 up do not need to be at the same moment of time. In the EstMB cohort the time of MB sample 347 collection varies between individuals, whereas in the EstBB cohort the start of follow-up is set 348 to 1st January 2015 for all individuals. The reason for the latter is that the history of antibiotics 349 usage is not properly recorded before 2005 in the electronic health records and the chosen 350 cut-off date allows us to analyse the antibiotics consumption during a 10-year period prior to 351 follow-up in the EstBB cohort. As we were interested in the long-term effects rather than the 352 extreme alterations that occur due to recent antibiotics usage, we excluded the individuals 353 who had been prescribed AB during the six months preceding either the start of MB sample 354 collection in EstMB or start of follow-up in EstBB.

355 Defining antibiotics usage and incident diseases

To characterise the long-term antibiotics usage, we quantified the number of antibiotics treatments prescribed in the period between the last 6 months and last 10 years before the microbiome sample collection or start of follow-up. All drugs with the Anatomical Therapeutic Chemical (ATC) classification code J01* were considered as antibiotics. We chose the 10year period similar to Aasmets & Krigul *et al.*², where we showed a cumulative long-term effect

of antibiotics usage. Additionally, we considered separately the history of usage of penicillins
 (ATC code J01CR), macrolides (J01FA) and fluoroquinolones (J01MA) since these classes

have the strongest long-term effects on gut microbiome (Aasmets et al., unpublished data).

364 We restricted the analysis to incident diseases, which we defined as the first occurrence of an 365 ICD-10 code of interest in the EHR after the start of follow-up (1st January 2015) until the end 366 of follow-up (31st December 2022). We focused primarily on the chronic common diseases 367 and cancers with at least 50 incident cases in the EstBB cohort. Summary of the selected 368 diseases is shown in **Supplementary Table 1**. Furthermore, we excluded from any analysis 369 of an incident disease the prevalent cases for the corresponding disease. We did not use any 370 other disease-specific exclusion criteria for the method demonstration. However, we do 371 encourage to utilise disease-specific exclusion criteria when a more thorough analysis of a 372 specific disease is of interest.

373 Main method

374 For inferring the causal effect of MB on disease we utilised the method of Two-Sample Two-375 Stage Least Squares (TSTSLS), which is a special case of instrumental variable regression 376 for the two-stage estimation in a two-sample setting. A detailed description of TSTSLS can be 377 found elsewhere³⁷. Rationale for using the two-sample setting is that the microbiome is often 378 measured in smaller samples compared to incident disease outcomes available in the large 379 biobank samples. Using TSTSLS allows us to leverage the information from such large 380 samples. We denote in the following formulas the estimated effect of instrument (hAB) on exposure (MB) as $\beta_{MB,hAB}$, instrument on outcome (D) as $\beta_{D,hAB}$, and exposure on outcome, 381 382 i.e. the causal relationship of interest, as $\beta_{D,MB}$. We estimate $\beta_{D,hAB}$ in the EstBB cohort 383 (Sample1) using the logistic regression model and $\beta_{MB,hAB}$ in the EstMB cohort (Sample2) 384 using the linear regression model. Thereafter we calculate the effect-estimate for the causal 385 relationship as a ratio of coefficients:

$$\beta_{D,MB} = \frac{\beta_{D,hAB}}{\beta_{MB,hAB}}.$$

Further, we calculate the standard deviation for the estimated $\beta_{D,MB}$ based on Pacini & Windmeijer³⁷ as:

389
$$\sigma_{D,MB} = \sqrt{\frac{\sigma_{D,hAB}^2 + \beta_{D,MB}^2 * \sigma_{MB,hAB}^2}{\beta_{MB,hAB}^2}}$$

where $\sigma_{D,hAB}^2$ is the variance of $\beta_{D,hAB}$ and $\sigma_{MB,hAB}^2$ is the variance of $\beta_{MB,hAB}$. We obtained the 390 391 p-values based on z-scores, calculated as $\beta_{D,MB}/\sigma_{D,MB}$, and standard normal distribution. Further, we calculated the confidence intervals for the estimates as $\beta_{D,MB} \pm 1.96 * \sigma_{D,MB}$. 392 393 To account for multiple testing, we used the Benjamini-Hochberg procedure to control for the 394 false discovery rate (FDR). We set the significance threshold for FDR-adjusted p-value to 0.05. 395 396

Model assumptions 397

- The obtained $\beta_{D,MB}$ is a valid causal estimate if the following assumptions are met³⁸: 398
- 399 AB usage history has an effect on MB:
- 400 AB usage history is not associated with any of the confounders of the microbiome-• 401 disease association;
- 402 There is no direct effect of AB usage history on incident disease outcomes outside of 403 the pathway via microbiome.
- 404 Possible violations of these assumptions are described in the Results section.

Sensitivity analyses 405

406 In the main analysis, we set the maximum number of antibiotics prescribed during the period 407 of interest to 5, minimum age to 23 and maximum age to 50. The lower limit for age refers to 408 the minimum age in the EstMB cohort. Subjects with impaired health might be more prone to 409 comorbidities and higher consumption of antibiotics. Thus, the aim of the initial restriction of 410 the age range and number of antibiotics used is to focus on the healthier part of the population 411 to address potential confounding. However, we pursued several sensitivity analyses to assess 412 the validity and robustness of the method:

- 413 1. We assessed the performance of the method in the setting, where we expect there to 414 be no association. For that we created pseudo-variables indicating disease 415 presence/absence for each individual in the EstBB sample by randomly sampling from 416 binomial distribution with predefined probability. In total we created 39 pseudo-417 variables with disease-probabilities ranging from 2.5% to 97.5% (Supplementary 418 Table 2). The purpose of the analysis was to check whether the proportion of 419 significant associations between randomly generated disease-variables and P/B ratio 420 remains below the nominal alpha-level of 5%.
- 421 2. To account for the feedback-mechanism of the disease whereby the disease might 422 actually already be prevalent for a period of time prior to diagnosis and could thus

423 already have an effect on the MB, we pursued a sensitivity analysis where we 424 considered the first 5 years of incidence after the start of follow-up as prevalent and 425 therefore excluded such individuals from the analysis (Supplementary Table 5). With 426 such sensitivity analysis we aim to eliminate bias originating from the feedback 427 mechanism of a disease that was already developing and affecting MB prior to the 428 diagnosis:

- 429 3. We assessed the relationships between MB and diseases while using specific AB 430 subgroups as instruments instead of total AB-usage. More specifically, we defined 431 three additional variables as instruments based on the usage of AB with following ATC-432 codes: J01FA (macrolides) (Supplementary Table 6), J01MA (fluoroquinolones) 433 (Supplementary Table 7), and J01CR (penicillins) (Supplementary Table 8). These 434 antibiotics classes were chosen since they have the strongest long-term effects on gut 435 microbiome (Aasmets et al., unpublished data). All three variables were uncorrelated 436 with each other (all Spearman correlations in EstMB and EstBB between the three AB-437 subgroups below 0.2 (Fig. 2B)), thus representing independent instruments. We 438 assumed to see in general similar patterns of associations between MB and diseases, 439 since a strong causal effect should not depend on the instrument used, provided that 440 the instrument is valid. For this sub-analysis we excluded all the individuals who were 441 prescribed any AB regardless of the ATC-code during 6 months prior to MB sample 442 collection or start of follow-up. These analyses were carried out similarly to the main 443 analysis with the maximum number of AB equal to 5 and age between 23 and 50.
- 444 4. Since the logarithm of the Prevotella-Bacteroides (P/B) ratio has a bimodal 445 distribution, we additionally performed an analysis where we applied inverse normal transformation on the P/B ratio prior to analysis using the RNOmni R package³⁹. 446 447 (Supplementary Table 9)

Data availability 448

449 The metagenomic data generated in this study have been deposited in the European Genome-450 Phenome (https://www.ebi.ac.uk/ega/) Archive database under accession code 451 EGAS00001008448. The phenotype data contain sensitive information from healthcare 452 registers and they are available under restricted access through the Estonian biobank upon 453 submission of a research plan and signing a data transfer agreement. All data access to the 454 Estonian Biobank must follow the informed consent regulations of the Estonian Committee on 455 Bioethics and Human Research, which are clearly described in the Data Access section at 456 https://genomics.ut.ee/en/content/estonian-biobank. A preliminary request for raw

457 metagenome and phenotype data must first be submitted via the email address
458 <u>releases@ut.ee</u>

459

460 All participants included in the EstBB cohort provided informed consent for the data and 461 samples to be used for scientific purposes. All participants have joined the Estonian Biobank on a voluntary basis and have signed a broad consent form, which allows to receive 462 463 participant's personal and health data from national registries and databases. Rights of gene 464 donors are regulated by Human Genes Research Act (HGRA) § 9 – Voluntary nature of gene 465 donation (https://www.riigiteataja.ee/en/eli/ee/531102013003/consolide/ current). This study 466 was approved by the Research Ethics Committee of the University of Tartu (approval No. 467 266/T10) and by the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs; approval No. 1.1-12/17 and 1.1-12/624). 468

469 Acknowledgements

This study was funded by the European Union through the European Regional Development
Fund Project No. 2014-2020.4.01.15-0012 GENTRANSMED. Data analysis was carried out
in part in the High-Performance Computing Center of University of Tartu.

473

The authors would like to thank Mari-Liis Tammeorg, Kreete Lüll, Marili Palover, Anu Reigo, Neeme Tõnisson, Liis Leitsalu, Triinu Temberg and Esta Pintsaar for participating in the sample collection process of the Estonian Microbiome cohort. We thank Steven Smit, Rita Kreevan and Martin Tootsi for the DNA extraction process. We thank Reidar Andreson for bioinformatic support. We also thank all the EstBB study participants.

479 Conflict of Interest

480 The authors declare that the research was conducted in the absence of any commercial or 481 financial relationships that could be construed as a potential conflict of interest.

482 Author Contributions


O.A., E.O. and K.F. conceptualised and supervised the study. O.A and N.T. designed the
study and performed the data analysis. N.T. and O.A. interpreted the data and prepared the
figures and wrote the manuscript. The EstBB Research Team provided the phenotype data.
All authors read and approved the final paper.

487 Funding

- 488 This work was funded by Estonian Research Council grants (PRG1414 to E.O. and PRG1197
- 489 to K.F.) and an EMBO Installation grant (No. 3573 to E.O.). K.F. was additionally funded from
- 490 the European Union's Horizon Europe research and innovation programme under grant
- 491 agreement No 964874.
- 492

493






Main AB-IVR - Main AB-IVR + inverse normal transformation

496 Supplementary figure 1. Results of the main analysis for all the 56 studied diseases. Colours 497 represent different data transformations for the Prevotella/Bacteroides ratio. Sensitivity analysis results 498 with the inverse normal transformation is shown in black.

499

500

495




◆ Main AB-IVR ◆ Up to 89y old ◆ Up to 10 antibiotics ◆ 5y gap

501 Supplementary figure 2. Results of the sensitivity analysis analysis for all the 56 studied 502 diseases. Green shows the effect estimates, when age is filtered as 23-89; light-purple shows the effect

503 estimates, when the maximum number of AB prescribed is 10; dark-purple describes the scenario 504 where the first five years of incidence after the start of follow-up is considered as prevalent disease.

505



506

Main AB-IVR - Combinations of penicillins - Macrolides - Fluoroquinolones

507 Supplementary figure 3. Results of the sensitivity analysis for all the 56 studied diseases. 508 Information regarding subclasses of AB were used instead of the total amount of AB prescribed, 509 whereas other settings were identical to the main analysis. Red corresponds to the main analysis with 510 the antibiotics combined, dark blue corresponds to the class of penicillins (J01CR), light-blue 511 corresponds to the class of macrolides (J01FA) and light-green corresponds to the class of 512 fluoroquinolones (J01MA).

- 513
- 514
- 515
- 516

517 References

- 518 1. Tarini Shankar Ghosh *et al.* Mediterranean diet intervention alters the gut microbiome in
- 519 older people reducing frailty and improving health status: the NU-AGE 1-year dietary
- 520 intervention across five European countries. *Gut* **69**, 1218 (2020).
- 521 2. Aasmets, O., Krigul, K. L., Lüll, K., Metspalu, A. & Org, E. Gut metagenome associations
- 522 with extensive digital health data in a volunteer-based Estonian microbiome cohort. *Nat.*
- 523 *Commun.* **13**, 869 (2022).
- 524 3. Gurung, M. et al. Role of gut microbiota in type 2 diabetes pathophysiology.
- 525 *EBioMedicine* **51**, 102590 (2020).
- 526 4. Aasmets, O. et al. Machine Learning Reveals Time-Varying Microbial Predictors with
- 527 Complex Effects on Glucose Regulation. *mSystems* **6**, e01191-20 (2021).
- 528 5. Ruuskanen, M. O. et al. Gut Microbiome Composition Is Predictive of Incident Type 2
- 529 Diabetes in a Population Cohort of 5,572 Finnish Adults. *Diabetes Care* **45**, 811–818 530 (2022).
- 531 6. Pascal, V. et al. A microbial signature for Crohn's disease. Gut 66, 813–822 (2017).
- 532 7. Wirbel, J. *et al.* Meta-analysis of fecal metagenomes reveals global microbial signatures
 533 that are specific for colorectal cancer. *Nat. Med.* 25, 679–689 (2019).
- 8. Kartal, E. *et al.* A faecal microbiota signature with high specificity for pancreatic cancer. *Gut* **71**, 1359–1372 (2022).
- 536 9. Ser, H.-L., Letchumanan, V., Goh, B.-H., Wong, S. H. & Lee, L.-H. The Use of Fecal
- 537 Microbiome Transplant in Treating Human Diseases: Too Early for Poop? *Front.*
- 538 *Microbiol.* **12**, 519836 (2021).
- 10. Lv, B.-M., Quan, Y. & Zhang, H.-Y. Causal Inference in Microbiome Medicine: Principles
 and Applications. *Trends Microbiol.* 29, 736–746 (2021).
- 541 11. Long, Y., Tang, L., Zhou, Y., Zhao, S. & Zhu, H. Causal relationship between gut
- 542 microbiota and cancers: a two-sample Mendelian randomisation study. *BMC Med.* **21**,
- 543 66 (2023).

- 544 12. Liu, B. et al. Two-Sample Mendelian Randomization Analysis Investigates Causal
- 545 Associations Between Gut Microbial Genera and Inflammatory Bowel Disease, and
- 546 Specificity Causal Associations in Ulcerative Colitis or Crohn's Disease. *Front. Immunol.*
- **13**, 921546 (2022).
- 548 13. Chen, M., Xie, C.-R., Shi, Y.-Z., Tang, T.-C. & Zheng, H. Gut microbiota and major
- 549 depressive disorder: A bidirectional Mendelian randomization. J. Affect. Disord. 316,
- 550 187–193 (2022).
- 14. Wade, K. H. & Hall, L. J. Improving causality in microbiome research: can human genetic
 epidemiology help? *Wellcome Open Res.* 4, 199 (2019).
- 553 15. Kurilshikov, A. et al. Large-scale association analyses identify host factors influencing
- human gut microbiome composition. *Nat. Genet.* **53**, 156–165 (2021).
- 555 16. Forslund, S. K. *et al.* Combinatorial, additive and dose-dependent drug–microbiome
 556 associations. *Nature* 600, 500–505 (2021).
- 17. Leitsalu, L. *et al.* Cohort Profile: Estonian Biobank of the Estonian Genome Center,
 University of Tartu. *Int. J. Epidemiol.* 44, 1137–1147 (2015).
- 18. Aasmets, O., Krigul, K. L. & Org, E. Evaluating the clinical relevance of the enterotypes
 in the Estonian microbiome cohort. *Front. Genet.* **13**, 917926 (2022).
- 561 19. Patangia, D. V., Anthony Ryan, C., Dempsey, E., Paul Ross, R. & Stanton, C. Impact of
- antibiotics on the human microbiome and consequences for host health.
- 563 *MicrobiologyOpen* **11**, (2022).
- 20. Chaudhari, S. N., McCurry, M. D. & Devlin, A. S. Chains of evidence from correlations to
 causal molecules in microbiome-linked diseases. *Nat. Chem. Biol.* 17, 1046–1056
- 566 (2021).
- 567 21. He, Q. et al. A causal effects of gut microbiota in the development of migraine. J.
- 568 *Headache Pain* **24**, 90 (2023).
- 569 22. Liu, B. *et al.* Assessing the relationship between gut microbiota and irritable bowel
- 570 syndrome: a two-sample Mendelian randomization analysis. *BMC Gastroenterol.* 23, 150
- 571 (2023).

- 572 23. Hughes, D. A. et al. Genome-wide associations of human gut microbiome variation and
- 573 implications for causal inference analyses. *Nat. Microbiol.* **5**, 1079–1087 (2020).
- 574 24. Zhang, J. et al. Association between gut microbiota and psoriasis: a bidirectional two-
- 575 sample Mendelian randomization study. https://www.researchsquare.com/article/rs-
- 576 3251626/v1 (2023) doi:10.21203/rs.3.rs-3251626/v1.
- 577 25. Dai, H. et al. Causal relationships between the gut microbiome, blood lipids, and heart
- failure: a Mendelian randomization analysis. *Eur. J. Prev. Cardiol.* **30**, 1274–1282
 (2023).
- 580 26. Hanssen, N. M. J., De Vos, W. M. & Nieuwdorp, M. Fecal microbiota transplantation in
- human metabolic diseases: From a murky past to a bright future? *Cell Metab.* 33, 1098–
 1110 (2021).
- 583 27. Li, J. *et al.* Gut microbiota dysbiosis contributes to the development of hypertension.
 584 *Microbiome* 5, 14 (2017).
- 28. Tan, P., Li, X., Shen, J. & Feng, Q. Fecal Microbiota Transplantation for the Treatment of
 Inflammatory Bowel Disease: An Update. *Front. Pharmacol.* **11**, 574533 (2020).
- 587 29. Vrieze, A. et al. Transfer of Intestinal Microbiota From Lean Donors Increases Insulin
- Sensitivity in Individuals With Metabolic Syndrome. *Gastroenterology* 143, 913-916.e7
 (2012).
- 30. Kootte, R. S. et al. Improvement of Insulin Sensitivity after Lean Donor Feces in
- 591 Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. *Cell*592 *Metab.* 26, 611-619.e6 (2017).
- 593 31. Zhang *et al.* Impact of Fecal Microbiota Transplantation on Obesity and Metabolic
- 594 Syndrome—A Systematic Review. *Nutrients* **11**, 2291 (2019).
- 595 32. Anthony, W. E. *et al.* Acute and persistent effects of commonly used antibiotics on the 596 gut microbiome and resistome in healthy adults. *Cell Rep.* **39**, 110649 (2022).
- 597 33. Maier, L. *et al.* Extensive impact of non-antibiotic drugs on human gut bacteria. *Nature*598 555, 623–628 (2018).
- 599 34. McGovern, A. S., Hamlin, A. S. & Winter, G. A review of the antimicrobial side of

- 600 antidepressants and its putative implications on the gut microbiome. Aust. N. Z. J.
- 601 *Psychiatry* **53**, 1151–1166 (2019).
- 602 35. Bruyndonckx, R. et al. Consumption of antibiotics in the community, European
- 603 Union/European Economic Area, 1997–2017. J. Antimicrob. Chemother. 76, ii7–ii13
- 604 (2021).
- 36. Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of diverse
- 606 microbial communities with bioBakery 3. *eLife* **10**, e65088 (2021).
- 37. Pacini, D. & Windmeijer, F. Robust inference for the Two-Sample 2SLS estimator. *Econ. Lett.* 146, 50–54 (2016).
- 609 38. Burgess, S. & Thompson, S. G. Mendelian randomization: methods for using genetic
- 610 *variants in causal estimation.* (CRC Press, 2015).
- 39. McCaw, Z. R., Lane, J. M., Saxena, R., Redline, S. & Lin, X. Operating characteristics of
- 612 the rank-based inverse normal transformation for quantitative trait analysis in genome-
- 613 wide association studies. *Biometrics* **76**, 1262–1272 (2020).